[Migraine as a cerebrovascular risk factor]. / Migraña como factor de riesgo cerebrovascular.

INTRODUCTION: Migraine has become an important vascular risk factor during the past few years, along with the presence of white matter and clinically silent ischaemic lesions. Whether these findings contribute to the migraine becoming chronic has been a source of debate. People with chronic migraine also have a less favourable metabolic profile. An exhaustive review of the literature has been made in order to try to clarify the relationship between migraine and vascular risk factors. DEVELOPMENT: Migraine, particularly with aura and in women < 45 years-old, is associated with an increased risk of cerebral infarction. This risk increases if the patient smokes or uses oral contraceptives. Migraine can also be a direct cause of a stroke, although it is an infrequent complication. Migraine with aura is associated with a risk factor of 12 of having subclinical infarctions in posterior fossa circulation. CONCLUSIONS: Since migraine is an independent vascular risk factor, a better control of migraine attacks, as well as other possible concomitant vascular risk factors, should decrease the likelihood of a stroke. Overall, the real risk of infarction is low, with 3.8 new cases per 100,000 women and year.

Generalized neck-shoulder hyperalgesia in chronic tension-type headache and unilateral migraine assessed by pressure pain sensitivity topographical maps of the trapezius muscle.

Spatial changes in pressure pain hypersensitivity are present throughout the cephalic region (temporalis muscle) in both chronic tension-type headache (CTTH) and unilateral migraine. The aim of this study was to assess pressure pain sensitivity topographical maps on the trapezius muscle in 20 patients with CTTH and 20 with unilateral migraine in comparison with 20 healthy controls in a blind design. For this purpose, a pressure algometer was used to assess pressure pain thresholds (PPT) over 11 points of the trapezius muscle: four points in the upper part of the muscle, two over the levator scapulae muscle, two in the middle part, and the remaining three points in the lower part of the muscle. Pressure pain sensitivity maps of both sides (dominant/non-dominant; symptomatic/non-symptomatic) were depicted for patients and controls. CTTH patients showed generalized lower PPT levels compared with both migraine patients (P = 0.03) and controls (P < 0.001). The migraine group had also lower PPT than healthy controls (P < 0.001). The most sensitive location for the assessment of PPT was the neck portion of the upper trapezius muscle in both patient groups and healthy controls (P < 0.001). PPT was negatively related to some clinical pain features in both CTTH and unilateral migraine patients (all P < 0.05). Side-to-side differences were found in strictly unilateral migraine, but not in those subjects with bilateral pain, i.e. CTTH. These data support the influence of muscle hyperalgesia in both CTTH and unilateral migraine patients and point towards a general pressure pain hyperalgesia of neck-shoulder muscles in headache patients, particularly in CTTH.

Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course.

The objectives of this study were: (1) to assess relative frequency of migraine in multiple sclerosis (MS) patients using the validated self-administered diagnostic questionnaire, and to compare the migraine rates in MS outpatients to age- and gender-matched historical population controls; (2) to compare clinical and radiographic characteristics in MS patients with migraine and headache-free MS patients. We conducted a cross-sectional study to assess the demographic profiles, headache features and clinical characteristics of MS patients attending a MS clinic using a questionnaire based on the American Migraine Prevalence and Prevention (AMPP) study. We compared the relative frequency of migraine in MS clinic patients and AMPP cohort. We also compared clinical and radiographic features in MS patients with migraine to an MS control group without headache. Among 204 MS patients, the relative frequency of migraine was threefold higher than in population controls both for women [55.7 vs. 17.1%; prevalence ratio (PR) =3.26, p<0.001] and men (18.4 vs. 5.6%; PR=3.29, p<0.001). In a series of logistic regression models that controlled for age, gender, disease duration, ß-interferon use, and depression, migraine in MS patients was significantly associated (p<0.01) with trigeminal and occipital neuralgia, facial pain, Lhermitte's sign, temporomandibular joint pain, non-headache pain and a past history of depression. Migraine status was not significantly associated with disability on patient-derived disability steps scale or T2 lesion burden on brain MRI. Migraine is three-times more common in MS clinic patients than in general population. MS-migraine group was more symptomatic than the MS-no headache group.

Epicrania fugax: an ultrabrief paroxysmal epicranial pain.

Ten patients (one man and nine women, mean age 48.8 +/- 20.1) presented with a stereotypical and undescribed type of head pain. They complained of strictly unilateral, shooting pain paroxysms starting in a focal area of the posterior parietal or temporal region and rapidly spreading forward to the ipsilateral eye (n = 7) or nose (n = 3) along a lineal or zigzag trajectory, the complete sequence lasting 1-10 s. Two patients had ipsilateral lacrimation, and one had rhinorrhoea at the end of the attacks. The attacks could be either spontaneous or triggered by touch on the stemming area (n = 2), which could otherwise remain tender or slightly painful between the paroxysms (n = 5). The frequency ranged from two attacks per month to countless attacks per day, and the temporal pattern was either remitting (n = 5) or chronic (n = 5). This clinical picture might be a variant of an established headache or represent a novel syndrome.

[Determinants of prophylactic migraine therapy in Spain]. / Determinantes del uso de los fármacos con indicación para la profilaxis de la migrana en España.

INTRODUCTION: Migraine interferes with the quality of life of patients. Prophylactic medication is an option to be considered in cases showing inefficiency of symptomatic medication or an increase in the number of attacks. AIM: To evaluate the characteristics of patients that start on prophylactic treatment for migraine. PATIENTS AND METHODS: A multicenter epidemiologic survey was conducted in 110 neurological outpatient clinics and hospitals among adult patients of both sexes who required prophylactic treatment for migraine. Pain intensity was measured through a three-category scale: mild, moderate, or severe. Daily disability was measured by a disability questionnaire. RESULTS: A total of 735 patients with migraine who had started prophylactic treatment were considered valid for the analysis. The patients reported an average of 9.7 days with migraine in the previous month, 32% of the episodes lasting more than 24 hours. Half of the patients referred working or home disability due to migraine with a total average score of 15.1 on the disability scale (grade III). A 48% of the patients had previously received prophylactic treatment, the medications most commonly prescribed being flunarizine, propranolol and amitriptyline. At the study visit, the most commonly prescribed medications were topiramate, flunarizine, propranolol, and amitriptyline. CONCLUSIONS: Our study reveals that starting prophylactic treatment is in the majority of cases due to a high attack frequency. A clear evolution is being observed in prophylactic medication prescription, with a shift from flunarizine or propranolol to topiramate, which is prescribed more frequently nowadays.

Assessment of deep dynamic mechanical sensitivity in individuals with tension-type headache: The dynamic pressure algometry.

BACKGROUND: To explore the validity of dynamic pressure algometry for evaluating deep dynamic mechanical sensitivity by assessing its association with headache features and widespread pressure sensitivity in tension-type headache (TTH). METHODS: One hundred and eighty-eight subjects with TTH (70% women) participated. Deep dynamic sensitivity was assessed with a dynamic pressure algometry set (Aalborg University, Denmark© ) consisting of 11 different rollers including fixed levels from 500 g to 5300 g. Each roller was moved at a speed of 0.5 cm/s over a 60-mm horizontal line covering the temporalis muscle. Dynamic pain threshold (DPT-level of the first painful roller) was determined and pain intensity during DPT was rated on a numerical pain rate scale (NPRS, 0-10). Headache clinical features were collected on a headache diary. As gold standard, static pressure pain thresholds (PPT) were assessed over temporalis, C5/C6 joint, second metacarpal, and tibialis anterior muscle. RESULTS: Side-to-side consistency between DPT (r = 0.843, p < 0.001) and pain evoked (r = 0.712; p < 0.001) by dynamic algometer was observed. DPT was moderately associated with widespread PPTs (0.526 > r > 0.656, all p < 0.001). Furthermore, pain during DPT was negatively associated with widespread PPTs (-0.370 < r < -0.162, all p < 0.05). DISCUSSION: Dynamic pressure algometry was a valid tool for assessing deep dynamic mechanical sensitivity in TTH. DPT was associated with widespread pressure sensitivity independently of the frequency of headaches supporting that deep dynamic pressure sensitivity within the trigeminal area is consistent with widespread pressure sensitivity. Assessing deep static and dynamic somatic tissue pain sensitivity may provide new opportunities for differentiated diagnostics and possibly a new tool for assessing treatment effects. SIGNIFICANCE: The current study found that dynamic pressure algometry in the temporalis muscle was associated with widespread pressure pain sensitivity in individuals with tension-type headache. The association was independent of the frequency of headaches. Assessing deep static and dynamic somatic tissue pain sensitivity may provide new opportunities for differentiated diagnostics and possibly a tool for assessing treatment effects.

Numular headache: a coin-shaped cephalgia.

Numular headache is a chronic, mild to moderate, pressurelike pain in a circumscribed cranial area of approximately 2 to 6 cm in diameter. Pain usually is limited to the parietal region, although it may appear in any cranial site. It is a benign process of usually unknown origin.

Native language shifts across sleep-wake states in bilingual sleeptalkers.

STUDY OBJECTIVES: To assess language used during episodes of sleeptalking in bilingual children. DESIGN: The investigation was accomplished through the parents who, after having received appropriate information, participated by filling out a survey on sleeptalking. SETTINGS: The study was performed in three bilingual schools of the Basque country, a region in northern Spain in which two completely different official languages are spoken. PATIENTS: A total of 1000 parents agreed to participate, and 681 children were studied. MEASUREMENTS AND RESULTS: Sleeptalking was reported by 383 (56.3%) of children (mean age 9 years; range: 3-17). Most individuals used their dominant (i.e., native) language during sleep. However, a minority (< 4%) were found to use their non-dominant language persistently during episodes of sleeptalking. CONCLUSIONS: Balanced bilinguals (those who have equal proficiency in both languages) may sleeptalk in either of the two languages. Dominant bilinguals (i.e., having greater proficiency in one language) may preferentially sleeptalk in their dominant language, with immediate past events probably influencing language use in individual subjects on particular nights. Several considerations are postulated as an explanation for the group who systematically exhibited a dominance shift during sleep.

Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves.

Greater occipital nerve (GON), supraorbital nerve (SON), and minor occipital nerve (MON) blockades-in this sequence-were carried out on the symptomatic side in patients with chronic paroxysmal hemicrania (CPH) (no = 6) and hemicrania continua (HC) (no = 7). Prior to the blockade, indomethacin was discontinued for a sufficiently long time (24 h) to allow a constant flow of attacks/constant pain. The local anaesthetic agent used was lidocaine. The blockades were invariably negative in CPH. In HC, the GON and MON blockades generally had no positive influence. The pattern as regards SON blockades was slightly different, in that the pre-test average VAS-value of 7.3 decreased to 4.6 (p < 0.05, Student's t-test, and p = 0.065 Wilcoxon) and-on an individual basis-decreased in 4 out of 7 patients. GON/MON blockades will help distinguish CPH/HC from cervicogenic headache. SON blockade will have to be carried out in a good-sized series of HC patients in order to establish more concrete evidence of the putative effect in HC. SON blockades may eventually also aid in the distinction between HC and supraorbital nerve neuralgia (where the blockade effect generally seems to be complete).

Sympathetic skin response: correlation with autonomic and somatic involvement in multiple sclerosis.

The sympathetic skin response (SSR) was studied in 63 multiple sclerosis (MS) patients, 54 with clinical definite and 9 with clinical probable form. The test was recorded from palms and soles and induced by electric stimulus. SSR was abnormal, absent or mildly delayed, in 26 patients (41%). The average score in the Kurtzke Expanded Disability Status Scale was higher in patients with abnormal SSR, showing a positive correlation with the latencies (p < 0.05). When compared to other evoked responses (somatosensory, brainstem auditory and visual evoked potentials), only visual evoked potentials showed a positive correlation (p < 0.05). Among the signs of autonomic dysfunction, bladder impairment was the most frequently associated with altered SSR (p < 0.05). These results could be probably due to the higher incidence of these abnormalities during the course of the disease. It is concluded that SSR is a simple test for a dynamic evaluation of MS, well correlated with the degree of disability, able to detect subclinical lesions in the sympathetic tracts, but with slight localizing value. It has also a low sensitivity for autonomic impairment related only with the bladder dysfunction. These facts exclude the SSR as a primary diagnostic tool in MS.

[Approach to the diagnosis and therapy of vascular neuropathy]. / Aproximación al diagnóstico y tratamiento de la neuropatía vasculítica.

Peripheral neuropathy is a very common clinical manifestation of vasculitis syndromes which may present as an early sign of such neuropathy or else may be the only such sign as in the case of non-systemic vascular neuropathy. The clinical affectation of the neuropathy depends on the extent and course of the ischaemic changes brought on by vasculitis, with multineuritis being the most usual presenting form of vascular neuropathy. Neurophysiological studies show the extent and severity of the neuropathy and often identify subclinical affectation representing a mixed pattern of affectation with axomal predominance. Nerve biopsy is a prerequisite for diagnosis, noting any infiltration by inflammatory cells and/or necrosis at perivascular and transmural levels together with vessel thrombosis or rechanneling. Using immunofluorescent techniques, immune deposits of IgG, IgM and components may be noted. Vasculitis neuropathy treatment is fundamentally carried out at the expense of corticosteroids and immunosuppressive which may be administered individually or in combination. In vasculitis neuropathy bad prognostic factors would include old age, the presence of kidney disease and delayed diagnosis and treatment.

[Acalculia. Neurological bases, evaluation and disorders]. / Acalculia. Bases neurológicas, evaluación y trastornos.

OBJECTIVE: To make a review of the literature on alterations in mathematical ability secondary to structural cerebral lesions. DEVELOPMENT AND CONCLUSIONS: We refer to the initial classification of acalculia of Berger (secondary acalculia when this is due to broader neuropsychological deficits and primary acalculia when it occurs alone) to the classical division of Hecaen (alexia and numerical agraphia with or without alterations in reading and writing of letters and words, visuo-spatial acalculia due to alterations in the spatial organization of multi-digit figures and the partial results of arithmetical operations, anarithmetia or primary failure in mathematical ability) and the most recent classifications based on neurocognitive models, which subdivide the acalculias into those secondary to changes in the system for processing numbers and those due to changes in the cognitive system for mathematics (McCloskey and Caramazza). Similarly, we review the correlations between the clinical changes in mathematics and the cerebral localization of the causative lesions (left parieto-temporal, right and including frontal and subcortical associative areas) together with the association of acalculia and other neuropsychological deficits. Finally we review the neuropsychological instruments available for the evaluation of acalculias, with particular reference to the tools validated and scaled for our language and sociocultural setting.

[Myelitis associated with varicella-zoster virus in the absence of cutaneous zoster]. / Mielitis asociada al virus varicela zoster en ausencia de zoster cutáneo.

INTRODUCTION: The spectrum of neurological complications associated with the infection by varicella-zoster virus (VVZ) is very broad. The diagnosis, usually based on clinical findings and their temporal relationship with cutaneous herpes zoster should be confirmed by serological and/or virological techniques. However, there are an increasing number of cases compatible with this diagnosis in the absence of a skin rash. CLINICAL CASE: We describe the case of a previously healthy woman of 27 who developed a neurological condition of subacute-chronic course, not preceded by a skin rash and compatible with the diagnosis of myelitis. She had had varicella at the age of 13. The MR of the medulla showed two hyperintense lesions in potentiated sequences in T2 at the level of the cervical medulla (segments C3-C4 and C6). Studies made to rule out other causes of myelopathy were normal or negative. After the first lumbar puncture there was an increase in the number of cells seen (up to 50/mm3) mainly mononuclear with oligoclonal bands, raised tibling index, antibodies (ab) IgG to VVZ and the indexes showing specificity to these abs and their intrathecal production were positive. Treatment with acyclovir produced no change in either her clinical condition or in the cerebrospinal fluid findings. CONCLUSION: One should consider the possibility of the association with VVZ in patients of any age, whether immunodeficient or not, who present any neurological syndrome for which no other aetiology has been found, whether or not it is preceded by a typical skin rash. The improvement of serological and virological methods permits precise diagnosis of the disorder.

[The hypothalamus in SUNCT syndrome: similarities and differences with the other trigeminal-autonomic cephalalgias]. / El hipotálamo en el SUNCT: similitudes y diferencias con las otras cefaleas trigeminoautonómicas.

INTRODUCTION: SUNCT belongs to the group of trigeminal-autonomic cephalalgias (TAC) --cluster headache and paroxysmal hemicranias--, since its shares a series of features with them. SUNCT was finally included in this group when the hypothalamus was proved to play a key role in its pathophysiology, an aspect that it has in common with other TAC. However, its clinical resemblance to trigeminal neuralgia of the first branch is notable, although it is accepted that the genesis of the trigeminal neuralgia is peripheral. DEVELOPMENT: The article presents the evidence available to date that has made it possible to associate the hypothalamus with SUNCT, as well as outlining its similarities and differences with respect to other TAC. This evidence is clinical, hormonal, from functional neuroimaging (activation of the posteroinferior hypothalamus) and from therapeutic outcomes (with deep hypothalamic stimulation). Likewise, a detailed description is provided of both the neuroanatomical bases (the hypothalamus as part of the neural networks involved in processes concerned with behaviour, memory, antinociceptive control, waking-sleep control and other circadian rhythms, etc.) and the neurochemical bases (orexins, somatostatin and endogenous opiates) that would support the hypotheses which researchers are attempting to establish to fit the evidence discussed earlier, which would have many points that overlap from one TAC to another. CONCLUSIONS: The question as to whether the hypothalamus is the/a generator of TAC or whether it is an element that allows its development remains open to debate, as does the issue of which would be the most plausible explanation for the phenotypic differences between them. Future studies will allow the enigma of SUNCT and the other TAC to be explained.

[A clinical approach to cranial neuralgias]. / Aproximación clínica a las neuralgias craneales.

INTRODUCTION: The International Association for the Study of Pain defines neuralgia as the pain that is felt in the distribution of a nerve or nerve root. Although the most important criterion for its diagnosis is spatial, distinguishing between neuralgia and other types of pain in the craniofacial area will only be possible by looking at a set of many clinical characteristics as a whole. DEVELOPMENT: Knowledge of the territories of sensory distribution of the nerves or roots is essential to be able to define the location of the pain in neuralgias. Other attributes are also useful for diagnosing them: the quality of the pain (paroxysmal, stinging-burning, dull), the time profile (seconds-minutes versus hours-days), the absence of accompanying phenomena other than certain manifestations of sensory dysfunction, especially in the symptomatic forms (hypoanaesthesia, paresthesias, dysesthesias, allodynia, hyperalgesia, hyperpathy), pain triggered by tactile or mechanical stimuli in the painful territory ('trigger' zones) or a positive Tinel's sign, the response to anaesthetic blockade of the nerve or root, and the response to certain drugs. CONCLUSIONS: Although trigeminal neuralgia is the most frequent, there are many other kinds of craniofacial neuralgias, in fact, theoretically, the total number is the same as the number of nerve roots and nerves responsible for the sensory innervation of these anatomical regions. It is essential to be familiar with them to obtain a correct diagnosis.

[Experience with intranasal zolmitriptan in cluster headache]. / Experiencia con zolmitriptán nasal en la cefalea en racimos.

INTRODUCTION: The objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache in daily clinical practice. PATIENTS AND METHODS: We collected a total of 18 patients with cluster headache and experience with intranasal zolmitriptan; 17 had used subcutaneous sumatriptan and 8 oral triptans. The main reasons for trying intranasal zolmitriptan were: poor tolerability in 12 patients and insufficient efficacy in 6. RESULTS: Among the 17 patients experienced in subcutaneous sumatriptan, 12 (71 %) preferred nasal zolmitriptan, 2 (18 %) subcutaneous sumatriptan and 2 (12 %) did not express any preference. The reasons for preferring intranasal zolmitriptan were: higher convenience (n = 6), better tolerability (n = 5), lower price (n = 2) and higher efficacy (n = 1). Seven out of the 8 patients who had taken oral triptans preferred nasal zolmitriptan, in all cases due to higher subjective efficacy. A total of 11 patients showed efficacy within 30 minutes. Only 3 patients referred to adverse events, always mild. CONCLUSIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache. This formulation should be considered in patients with poor tolerability to subcutaneous sumatriptan and in those attacks where quick access to inhaled oxygen is not possible. These results suggest that a controlled trial with nasal zolmitriptan in this indication would be worthwhile.

[Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients]. / Tratamiento sintomático de la migraña con zolmitriptán: experiencia con 82 pacientes.

OBJECTIVES: To analyze our experience with the new, 5 mg intranasal formulation of zolmitriptan in the symptomatic treatment of migraine attacks. PATIENTS AND METHODS: This series includes 82 patients who had treated an average of 7 migraine attacks. Eighty patients had taken oral triptans and 20 subcutaneous sumatriptan. The main reasons for using nasal zolmitriptan were: poor efficacy of oral triptans (41.5 % of the patients), use of subcutaneous sumatriptan (24.4%) or medical criteria (34.5%). RESULTS: Among the 80 patients who had been treated with oral triptans, 50 (62.5 %) preferred nasal zolmitriptan, 14 (17.5 %) oral triptans and the remaining 16 (20 %) did not express any preference. The main reasons for this preference were shorter speed of action and better efficacy. Within those 20 patients who were using subcutaneous sumatriptan, 8 (40 %) preferred subcutaneous sumatriptan, 5 (25%) nasal zolmitriptan and 7 (35%) did not express any preference. The reasons for preference of intranasal zolmitriptan over subcutaneous sumatriptan were greater convenience, better tolerability and lower price. A total of 55 patients noticed efficacy within 60 min. Half experienced at least one adverse event, always mild. The most frequent were local: bad taste (n=23) or nasal irritation/itching (n=8). CONCLUSIONS: The new intranasal formulation of 5 mg zolmitriptan is a good option for the symptomatic treatment of migraine, which could be considered as an intermediate between oral triptans and the subcutaneous formulation of sumatriptan.

Duration of attacks of first division trigeminal neuralgia.

Objective measurements of duration of attacks have been performed in 8 (5 female and 3 male) patients suffering from primary first division (V-1) trigeminal neuralgia. The mean age of the patients was 67.5 +/- 11.4 years, and the mean age at onset 64.0 +/- 9.7 years. During the study the patients were off treatment. A total of 192 attacks were witnessed by the authors and exactly timed by a stop-watch. The duration of attacks ranged from 2 to 32 s, with a mean of 6.5 +/- 6.1 s. The unweighted mean was 8.8 +/- 5.7 s, with a range of 2.4-17.5 s. With the present data the duration of attacks of V-1 neuralgia has been exactly determined, and the clinical distinction of V-1 neuralgia from other shortlasting headaches, particularly from SUNCT, has been substantially clarified.